All

The century of the microbiome: an exciting time for human health
26 January 2021

The century of the microbiome: an exciting time for human health

While the pandemic might have caused some disruption, microbiome research hasn’t slowed down at all, notes Isabelle de Cremoux, CEO and Managing Partner, Seventure...

Read more
‘Significant interest’: Venture capital major Seventure Partners extends €200m+ microbiome fund
13 January 2021

‘Significant interest’: Venture capital major Seventure Partners extends €200m+ microbiome fund

European life sciences investment firm Seventure Partners has extended the final close of its second microbiome innovation fund and increased focus on advances in the skin...

Read more
Health for Life Capital Fund, managed by Seventure Partners, increases focus on skin microbiome in its portfolio
11 January 2021

Health for Life Capital Fund, managed by Seventure Partners, increases focus on skin microbiome in its portfolio

Seventure Partners, one of Europe’s leaders in financing innovation and a world leader in life science microbiome investment, has increased focus on skin microbiome...

Read the press release
Pioneering a full-ecosystem microbiota approach to improve survival outcomes in life-threatening diseases by Hervé Affagard (Maat Pharma) published on europeanpharmaceuticalreview.com
16 December 2020

Pioneering a full-ecosystem microbiota approach to improve survival outcomes in life-threatening diseases by Hervé Affagard (Maat Pharma) published on europeanpharmaceuticalreview.com

Pioneering a full-ecosystem microbiota approach to improve survival outcomes in life-threatening diseases by Hervé Affagard (Maat Pharma) published on...

Read more
DERMALA Announces $6.73 Million Series A Financing to Expand and Scale Company’s Personalized Microbiome-Based Solutions for Acne and Other Skin Conditions
9 November 2020

DERMALA Announces $6.73 Million Series A Financing to Expand and Scale Company’s Personalized Microbiome-Based Solutions for Acne and Other Skin Conditions

A consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, announced today that it has closed a $6.73 million...

Read more
BiomX has dosed their first subject in their Phase 1a study of BX002 phage therapy for IBD
3 November 2020

BiomX has dosed their first subject in their Phase 1a study of BX002 phage therapy for IBD

BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the...

Read more
Animab, a venture spin-off from VIB, announces today that it has successfully concluded a 3.4 M€ seed financing round
27 October 2020

Animab, a venture spin-off from VIB, announces today that it has successfully concluded a 3.4 M€ seed financing round

Animab, a venture spin-off from VIB, announces today that it has successfully concluded a 3.4 M€ seed financing round. The company develops monoclonal antibodies for oral...

Read the press release
LARQ, leading health and wellness hydration brand, announced today a round closure of $10 million in Series A funding
29 September 2020

LARQ, leading health and wellness hydration brand, announced today a round closure of $10 million in Series A funding

LARQ was started with a simple vision where innovative technology can be combined with inspirational design to help people access pristine drinking water easily and...

Read the press release